Company: AGIO
Filing Date: 2025-04-25
Form Type: DEF 14A
Source: 0001193125-25-096719
Chunk: 121

Company: AGIOS PHARMACEUTICALS, INC.
Filing Date: 2025-04-25
Form: DEF 14A
Chunk 121
---
 value), under the terms of our Non-EmployeeDirector Compensation Policy.

| Name and Position                                                                        
 Brian Goff, Chief Executive Officer                                                      
 Cecilia Jones, Chief Financial Officer                                                   
 James Burns, Chief Legal Officer                                                         
 Sarah Gheuens, M.D., Ph.D., Chief Medical Officer, Head of Research and Development      
 Tsveta Milanova, Chief Commercial Officer                                                
 All current executive officers as a group                                                |     | Dollar Value |         — 
         — 
         — 
         — 
         — 
         — |    |     | Number of Shares of Common           
 Stock Underlying Stock Option Awards | — 
 — 
 — 
 — 
 — 
 — |    |     | Number of Shares of Common  
 Stock Underlying RSU Awards | — 
 — 
 — 
 — 
 — 
 — |    |
|:-----------------------------------------------------------------------------------------|:----|:-------------|----------:|---:|:----|:-------------------------------------|:--|---:|:----|:----------------------------|:--|---:|
| All current directors who are not executive officers as a group                          |     | $            | 3,200,000 | -1 |     |                                      | — | -2 |     |                             | — | -2 |
| All employees, including all current officers who are not executive officers, as a group |     |              |         — |    |     |                                      | — |    |     |                             | — |    |

| (1) | Represents the aggregate dollar value of annual equity awards to be granted in 2025 to each then-serving non-employee director. Under our Non-Employee Director Compensation Policy, each non-employee director who is serving on our board of directors immediately following our annual meeting of stockholders will receive $400,000 in equity awards on the date of such meeting (consisting of approximately 75% in stock options and 25% in RSUs, based on grant date fair value). The amount set forth in the Dollar Value column above equals $400,000 multiplied by the eight current non-employee directors (including the two non-employee directors who are standing for election at the Annual Meeting, which election is more fully described in Proposal 1 of this Proxy Statement). The amount excludes (i) any equity awards that the non-employee directors will be entitled to receive under our Non-Employee Director Compensation Policy for subsequent years following 2025 and (ii) any discretionary equity awards that any non-employee director may be awarded